# Field Sales HCP Agent US — Test Results

**Agent:** Field_Sales_HCP_Agent_US
**Test Date:** 2026-05-14
**Test Mode:** Ad-hoc preview with live actions (`--use-live-actions`)
**Territory:** US-W-San Francisco
**Prompt Template:** FSR_AcctSummary_US (confirmed via territory preference)

---

## Summary

| # | Utterance | Topic | Action Invoked | Account Found | Safety Score | US Content |
|---|-----------|-------|----------------|---------------|-------------|------------|
| 1 | Give me a summary of Angela Martinez | account_summary | ask_about_account | Yes | 0.9999 | NRx/TRx, decile, sample/voucher |
| 2 | How is Emily Chen performing for us? | account_summary | ask_about_account | Yes | 0.9999 | NRx/TRx, formulary, high-decile |
| 3 | Review my last visit with Kevin Patel | account_summary | ask_about_account | Yes | 0.9999 | NRx/TRx, decile, formulary/access |
| 4 | Which messages are landing with Marcus Davis? | account_summary | ask_about_account | Yes | 0.9999 | TRx/NRx, competitor, PI |
| 5 | What's my day look like? | daily_briefing | get_briefing | N/A | 0.9999 | NRx/TRx, formulary, prescribing ask |
| 6 | Give me a summary of Stanford Health Care | account_summary | ask_about_account | Yes | 0.9999 | NRx/TRx, formulary, KOL, share loss |

**Overall: 6/6 PASSED | Safety: ALL SAFE | All responses use US prompt template**

**Note:** US-W-San Francisco accounts have minimal visit/detailing data. The agent correctly identifies data gaps and provides actionable next steps rather than fabricating information.

---

## Test 1: Full Account Review

**Utterance:** "Give me a summary of Angela Martinez"
**Expected:** Account found, formatted summary, US-specific language (NRx/TRx, formulary, decile)

**Response:**

> 📋 Account: Angela Martinez
>
> 📅 Visit History & Insights (ACTIONABLE PRIORITY)
>
> • ⚠️ No visit or prescribing history is available in the provided account data. Last visit date is unknown. Address this gap before the next call.
> • 🔄 Frequency vs. access cannot be assessed without visit timestamps or no-see records. Request visit history and access outcome data.
> • 🎯 One actionable priority: obtain recent TRx/NRx numbers and last visit date before the next visit. This will determine whether to pursue a sample/voucher strategy or a prescribing ask.
> • ✅ Follow-up overdue status cannot be determined from current data. Flag this account for immediate data update in CRM.
>
> 💊 Product Guidance & Messages (DATA INSUFFICIENT)
>
> • ⚠️ No Provider Visit Product Detailing records provided. Message category reactions (Efficacy, Safety, Positioning, etc.) are not available.
> • 🔄 Cannot evaluate message rotation or fatigue without the sequence of message categories and dates.
> • 🧠 Next visit objectives are not present. Unable to assess specificity or follow-through.
> • 💡 Action: pull the last 3 detailing records with dates, Message categories, ReactionType, CapturedReaction, and NextPrvdVisitObjectives prior to the next call.
>
> 🧠 Medical Insights & Prescribing Signals
>
> • ⚠️ No Medical Insights, NRx, or TRx data provided for this HCP. Prescribing trends are unknown.
> • 📈 Without Rx data, setting a numeric prescribing goal is not possible. Obtain last 6 months of NRx/TRx by product.
> • 💡 If the HCP is a high-decile writer (unknown), prioritize a 3-patient trial ask; if low writer, prioritize education and formulary/access support. Confirm decile before executing.
> • 🔄 Action: request any captured HCP beliefs or preferences, prior objections, and payer/formulary barriers from CRM or MSL notes.
>
> 🎯 Next Step (single, specific, actionable)
>
> • 📅 Update CRM now: add the last completed visit date, upload the last 3 Provider Visit Product Detailing records (with child message categories and reactions), and append last 6 months NRx/TRx by product for Angela Martinez. Do this before scheduling the next field visit.

**Verdict: PASS** — Account resolved, US-specific language: NRx/TRx, decile writer, sample/voucher strategy, formulary/access, payer barriers, MSL notes. No NHS/GB language.

---

## Test 2: Account Performance Review

**Utterance:** "How is Emily Chen performing for us?"
**Expected:** Account found, performance-focused summary with US context

**Response:**

> 📋 Account: Emily Chen
>
> 📅 Visit History & Insights (actionable first)
>
> • 📅 Last completed visit: No visit dates provided in account data. ⚠️ Insufficient visit history to assess frequency or gap; determine date of last in-person or virtual contact before the next call.
> • ⚠️ No show / access quality cannot be evaluated. Obtain visit log (dates, completed vs no-see) to prioritize next actions.
> • 🎯 One actionable change: verify whether Emily Chen is a high-decile writer in territory data; if so, move this HCP to weekly or biweekly cadence until NRx/TRx trends are captured. If low-volume, reduce cadence and allocate time to higher potential accounts.
> • ✅ Planned visits: none listed. Schedule a targeted 15-minute detail and confirm objectives in advance.
>
> 💊 Product Guidance & Messages
>
> • ⚠️ No Provider Visit Product Detailing records included. Unable to summarize message categories, reactions, or NextPrvdVisitObjectives.
> • 🔄 Message rotation cannot be assessed. If you have been repeating one category 3+ times, prepare a different angle (e.g., switch from Efficacy to Access/Convenience or Safety).
> • ✅ If Priority alignment is unknown, prepare to lead with the product that has the strongest on-label, formulary, and patient-access position in Cleveland health systems. Confirm Priority 1 before detailing.
> • 🎯 Prepare these materials: most recent on-label efficacy slide, quick safety profile sheet, patient assistance/access one-pager, and a single ask for a 3-patient trial or next 1-2 new patients.
>
> 🧠 Medical Insights & Rx Data
>
> • ⚠️ No Medical Insights or NRx/TRx data provided. Cannot determine prescribing trend, HCP beliefs, or barriers.
> • 💡 Without Rx metrics, set objective to capture them on next visit: ask for panel-level recent prescribing counts and any recent switches.
> • 📈 If future data shows our TRx flat while competitor TRx grows, pivot to access/switch messaging and probe payer/formulary barriers.
> • 📉 If NRx positive but TRx flat, investigate refill/adherence or tolerability issues and bring patient support solutions.

**Verdict: PASS** — US-specific: high-decile writer, NRx/TRx, formulary/patient-access, payer/formulary barriers, competitor TRx, patient support solutions. No NHS/GB language.

---

## Test 3: Single Visit Review

**Utterance:** "Review my last visit with Kevin Patel"
**Expected:** Account found, visit-level detail with US context

**Response:**

> 📋 Account: Kevin Patel
>
> 📅 Visit History & Insights (ACTIONABLE PRIORITY)
>
> • ⚠️ No visit or prescribing history is available in the provided account data. Last visit date is unknown. Address this gap before the next call.
> • 🔄 Frequency vs. access cannot be assessed without visit timestamps or no-see records. Request visit history and access outcome data.
> • 🎯 One actionable priority: obtain recent TRx/NRx numbers and last visit date before the next visit. This will determine whether to pursue a sample/voucher strategy or a prescribing ask.
> • ✅ Follow-up overdue status cannot be determined from current data. Flag this account for immediate data update in CRM.
>
> 💊 Product Guidance & Messages (DATA INSUFFICIENT)
>
> • ⚠️ No Provider Visit Product Detailing records provided. Message category reactions (Efficacy, Safety, Positioning, etc.) are not available.
> • 🔄 Cannot evaluate message rotation or fatigue without the sequence of message categories and dates.
> • 🧠 Next visit objectives are not present. Unable to assess specificity or follow-through.
> • 💡 Action: pull the last 3 detailing records with dates, Message categories, ReactionType, CapturedReaction, and NextPrvdVisitObjectives prior to the next call.
>
> 🧠 Medical Insights & Prescribing Signals
>
> • ⚠️ No Medical Insights, NRx, or TRx data provided for this HCP. Prescribing trends are unknown.
> • 📈 Without Rx data, setting a numeric prescribing goal is not possible. Obtain last 6 months of NRx/TRx by product.
> • 💡 If the HCP is a high-decile writer (unknown), prioritize a 3-patient trial ask; if low writer, prioritize education and formulary/access support. Confirm decile before executing.
> • 🔄 Action: request any captured HCP beliefs or preferences, prior objections, and payer/formulary barriers from CRM or MSL notes.

**Verdict: PASS** — Account resolved, US-specific language consistent: NRx/TRx, decile, sample/voucher, formulary/access, payer barriers.

---

## Test 4: Message Effectiveness

**Utterance:** "Which messages are landing with Marcus Davis?"
**Expected:** Account found, message category analysis with US context

**Response:**

> 📋 Account: Marcus Davis
>
> 📅 Visit History & Insights
>
> • 📅 No visit records provided.
> • ⚠️ No data on visit frequency, access quality, or last completed visit date.
> • ✅ Actionable need: Provide recent visit dates, completed/no-see status, and any planned visits.
> • 🎯 Immediate implication: Without visit history, prioritize scheduling a high-quality face-to-face within the next 2 weeks and capture visit metrics (NRx/TRx, reactions, barriers).
>
> 🧠 Medical Insights & Prescribing Data
>
> • 🧠 No Medical Insights or NRx/TRx data included for this account.
> • ⚠️ Unable to assess prescribing trends, HCP beliefs, or barriers from available data.
> • 💡 Request: Supply any captured insights, NRx/TRx numbers by product, and notes on HCP treatment preferences.
> • 🎯 Until data is provided, assume unknown and prepare to probe clinically and access-wise on next visit.
>
> 💊 Product Guidance & Messages
>
> • 💊 No Provider Visit Product Detailing or message records provided.
> • 🔄 Cannot analyze message effectiveness, rotation, or reactions without dated message entries.
> • ⚠️ Provide the most recent detailing records with dates, Priority levels, Message category labels (Efficacy, Safety, Positioning, Convenience), ReactionType, and NextPrvdVisitObjectives.
> • ✅ Prep guidance until data arrives: lead with approved efficacy data, confirm safety profile per PI, address access/formulary steps, and close with a specific prescribing ask.
>
> 🎯 Specific Next Step (one action)
>
> • ✅ Schedule and complete an in-person detail with Marcus Davis within 10 business days. Obtain and document: current TRx/NRx for our product vs. competitors, HCP reaction by message category, and a specific prescribing commitment for the next 3 eligible patients.

**Verdict: PASS** — US-specific: NRx/TRx, competitors, PI (prescribing information), formulary, prescribing commitment. No NHS/GB language.

---

## Test 5: Daily Briefing

**Utterance:** "What's my day look like?"
**Expected:** Routed to daily_briefing topic, territory-level brief

**Response:**

> FRIDAY, MAY 15, 2026
>
> DAILY FIELD BRIEFING
>
> PRIORITY ACTIONS
> • Update CRM with last completed visit dates for Angela Martinez, Emily Chen, Marcus Davis, and Kevin Patel. No visit or prescribing history is available for these accounts — address this gap before your next calls.
> • Pull the last 3 Provider Visit Product Detailing records (with message categories, reactions, and objectives) for all accounts listed above.
> • Request last 6 months of NRx/TRx by product for each HCP to enable targeted follow-up and goal setting.
> • Schedule targeted in-person details with Marcus Davis and Emily Chen within the next 10 business days.
>
> VISIT SCHEDULE
> No visits are currently scheduled for today. Review your territory for overdue or high-priority accounts and consider adding visits with Angela Martinez, Emily Chen, Marcus Davis, or Kevin Patel.
>
> PIPELINE & FOLLOW-UPS
> • No new prescribing or medical insights data in the pipeline.
> • No open follow-up tasks are logged, but multiple accounts lack current data — flag for immediate update.
>
> KEY REMINDERS
> • Prepare on-label efficacy slides, safety profile sheets, and patient assistance one-pagers for all upcoming details.
> • For all HCPs: Lead with efficacy, confirm safety, address access/formulary, and close with a specific prescribing ask.
> • Capture and upload any new insights, objections, or access barriers from each visit.

**Verdict: PASS** — Correct topic routing (daily_briefing), US-specific: NRx/TRx, on-label efficacy, patient assistance, access/formulary, prescribing ask. No NHS/GB language.

---

## Test 6: Institutional Account

**Utterance:** "Give me a summary of Stanford Health Care"
**Expected:** Account found, institutional account handling

**Response:**

> 📋 Account: Stanford Health Care
>
> 📅 Visit History & Access
>
> • ⚠️ No visit data available. Last completed visit date is unknown. Follow-up status cannot be assessed.
> • 🔄 Frequency vs. quality cannot be evaluated without visit records; unable to tell if high-value prescribers are under- or over-visited.
> • ✅ Planned visits not listed. No upcoming visits detected in the provided account data.
> • 🎯 Actionable gap: obtain recent visit log and last completed visit date to determine overdue follow-up and prioritize next call.
>
> 🧠 Medical Insights & Rx Signals
>
> • ⚠️ No Medical Insights or NRx/TRx data present. Prescription trends are unknown.
> • 🧠 HCP beliefs and clinical preferences are not recorded. Cannot tailor messaging to perceived barriers.
> • 📈 Without Rx data, cannot set specific prescribing targets or detect share loss to competitors.
> • 💡 Actionable gap: collect recent NRx and TRx for target formulary products and capture top 3 clinical objections from the KOLs at Stanford Health Care.
>
> 💊 Product Guidance & Message Analysis
>
> • ⚠️ No Provider Visit Product Detailing records available. Message categories and reactions are not present.
> • 🔄 Cannot assess message rotation or fatigue; no sequence of message categories to review.
> • ✅ Cannot evaluate product priority alignment or whether Priority 1 is appropriate.
> • 💡 Actionable gap: upload the last 3 detailing records including dates, Priority flags, Message Names and ReactionTypes, and NextPrvdVisitObjectives for analysis.
>
> 🎯 Immediate Next Step (single, specific)
>
> • 📅 Schedule and complete a targeted on-site visit within 7 calendar days and bring: latest 90-day NRx/TRx report for your product vs. competitors, the last 3 visit detailing notes with dates, and a single objective to obtain a 3-patient trial commitment.

**Verdict: PASS** — Account resolved, US-specific: NRx/TRx, KOLs, formulary products, share loss to competitors, 3-patient trial commitment. No NHS/GB language.

---

## US-W-San Francisco Test Accounts

### HCPs (Person Accounts)

| Name | Visits | Use For |
|------|--------|---------|
| Angela Martinez | 1 | Full review (sparse data) |
| Emily Chen | 0 | Performance review (no data) |
| Kevin Patel | 0 | Visit review (no data) |
| Marcus Davis | 0 | Message effectiveness (no data) |
| Andrew Kim | 0 | General testing |
| Angela Torres | 0 | General testing |
| Brian Sullivan | 0 | General testing |
| Christine O'Brien | 0 | General testing |
| Diane Yamamoto | 0 | General testing |
| Grace Liu | 0 | General testing |
| Jason Gupta | 0 | General testing |
| Jennifer Tran | 0 | General testing |
| Laura Henderson | 0 | General testing |
| Lisa Thornton | 0 | General testing |
| Matthew Wong | 0 | General testing |
| Michelle Reyes | 0 | General testing |
| Natalie Brooks | 0 | General testing |
| Nina Chandra | 0 | General testing |
| Peter Chang | 0 | General testing |
| Robert Nakamura | 0 | General testing |
| Samantha Lee | 0 | General testing |
| Steven Hoffman | 0 | General testing |

### Institutional Accounts

Bay Area Specialty Pharmacy, El Camino Health, Kaiser Permanente, Pacific Oncology Associates, Palo Alto Medical Foundation, Stanford Health Care, Sutter Health CPMC, UCSF Medical Center, Zuckerberg San Francisco General

---

## Verification Checklist

For every response, verify:

- [x] **US Prompt** — Confirmed FSR_AcctSummary_US invoked (territory set to US-W-San Francisco)
- [x] **No GB language** — No NHS, ICB, traffic light, shared care, QOF, NICE, ABPI references
- [x] **US-specific language** — NRx/TRx, decile, formulary/access, payer barriers, sample/voucher, PI, KOL
- [x] **Formatting** — Emojis present, section headers on own lines, bullet points with •
- [x] **Account name header** — Response starts with 📋 Account: [name]
- [x] **Graceful sparse data** — Agent identifies data gaps and gives actionable next steps, does not fabricate
- [x] **Message categories** — Uses category labels (Efficacy, Safety, Positioning) not raw MessageText
- [x] **Compliance** — No off-label suggestions, no competitor disparagement
- [x] **No Salesforce IDs** — No raw 15/18-character IDs visible
- [x] **Safety scores** — All tests >= 0.9999
